Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avis Budget Group, Inc. - CAR
10:00am, Saturday, 01'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ:CAR). Such investors ar
The Schall Law Firm Invites Shareholders With Losses In Avis Budget Group, Inc. To Join A Securities Fraud Investigation
11:00am, Friday, 28'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Bud
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Comp
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
07:15pm, Thursday, 27'th Feb 2025
SHANGHAI , Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Comp
An Investigation Has Commenced on Behalf of Avis Budget Group, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CAR Losses.
10:30am, Wednesday, 26'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possi
FIX-IT DAY 2025: FREE CAR REPAIRS FOR LOS ANGELES RESIDENTS IN NEED
09:06am, Wednesday, 26'th Feb 2025
CarParts.com, Safe Parking LA & Partners Unite to Provide Critical Auto Repairs For Individuals and Families Facing Hard Times TORRANCE, Calif. , Feb. 26, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASD
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
08:00am, Wednesday, 26'th Feb 2025
SAN JOSE, Calif. , Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avis Budget Group, Inc. - CAR
06:00pm, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ: CAR). Such investors are adv
Avis Budget Group, Inc. (CAR) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
10:45am, Tuesday, 25'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possi
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Bud
Bronstein, Gewirtz & Grossman, LLC Encourages Avis Budget Group, Inc. (CAR) Shareholders to Inquire about Securities Investigation
10:00am, Tuesday, 25'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Comp
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
08:00am, Tuesday, 25'th Feb 2025
SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
10:53pm, Monday, 24'th Feb 2025
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
